Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.